I-mab Form 4 insider transactions

Phillip Andrew Dennis, Chief Medical Officer of I-Mab, sold 8,209 shares of common stock on September 17, 2026 for $0.71 per share.

Sean Wuxiong Cao, Chief Bus. Development Officer of I-Mab, sold 107,978 shares of common stock on September 9, 2026 for $0.74 per share.

Sean Wuxiong Cao, Chief Bus. Development Officer of I-Mab, reported multiple transactions in common stock on September 3, 2026.

Cong Claire Xu, EVP, Clinical Development of I-Mab, sold 3,282 shares of common stock on August 30, 2026 for $0.79 per share.

Robert A. Lenz, a Director of I-Mab, reported multiple transactions in common stock on August 22, 2026.

Mark Hagler, Chief Commercial Officer of NovaBridge Biosciences, received a significant stock option grant on July 8, 2026, as detailed in a Form 4 filing.

Lin Liwei Lorraine, General Counsel at NovaBridge Biosciences, received a significant employee stock option grant.

NovaBridge Biosciences CEO Srishti Gupta reports the acquisition of 3,000,000 employee stock options with an exercise price of $2.01.

Claire Xu Cong, SVP of Clinical Development at NovaBridge Biosciences, reported transactions involving ordinary shares and restricted stock units.

Director Fu Wei of NovaBridge Biosciences reported transactions involving employee stock options and restricted stock units.

Sean Wuxiong Cao, a Director and Chief Business Development Officer at NovaBridge Biosciences, reported significant equity transactions including the acquisition of Restricted Stock Units and Employee Stock Options.

SVP of Clinical Development Claire Xu reported the exercise of restricted stock units and a subsequent sale of shares.

Sean Wuxiong Cao, a Director and Chief Business Development Officer at NovaBridge Biosciences, reported a transaction involving the sale of ordinary shares.

Mark Arnold Hagler, an officer at NovaBridge Biosciences, acquired 230,000 ordinary shares in a series of transactions.